Cresco Labs Inc. (CRLBF) EBIT (2020 - 2026)

Cresco Labs (CRLBF) has reported EBIT for 7 consecutive years, with $13.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 17.22% year-over-year to $13.4 million; the trailing twelve-month figure through Jun 2026 stood at -$33.2 million (down 143.96% YoY), and the FY2025 full-year result was -$28.0 million, down 126.08% from the prior year.
• EBIT advanced to $13.4 million in Q2 2026 per CRLBF's latest filing, from $11.2 million in the prior quarter.
• Across five years, EBIT topped out at $32.4 million in Q2 2024 and bottomed at -$143.5 million in Q4 2022.
• Historically, EBIT has averaged -$3.8 million across 5 years, with a median of $16.2 million in 2022.
• The sharpest annual moves came in 2022 and 2024: EBIT slumped 1022.28% in 2022, then soared 713.25% in 2024.
• Over 5 years, EBIT stood at -$143.5 million in 2022, then jumped by 118.89% to $27.1 million in 2023, then declined by 28.39% to $19.4 million in 2024, then tumbled by 489.29% to -$75.5 million in 2025, then jumped by 117.69% to $13.4 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $13.4 million, $11.2 million, and -$75.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.